ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Targeting
Open access · greenAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 104 citations in OpenAlex.
- Trastuzumab Deruxtecan in Patients WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Cellular immunotherapy for lung cancer: current clinical evidence, translational challenges, and future perspectives: a narrative review.Translational cancer research · 2026Article
- Exceptional Response of HER2-Positive Breast Cancer to Osimertinib: A Case Report.Thoracic cancer · 2026Article
- Osimertinib-induced acute decompensated heart failure: a case report and review of the literature.Journal of medical case reports · 2026Review
- Are lazertinib and osimertinib comparable for treating advancedJournal of thoracic disease · 2026Article
- Case Report: Complete metabolic responses to trastuzumab-deruxtecan in HER2-altered solid tumors: two illustrative cases.Frontiers in immunology · 2026Article
- Comprehensive genomic landscape of ERBB2 in Chinese GI tumors: mutation-centered landscapes and precision treatment opportunities.Therapeutic advances in medical oncology · 2026Article
- Case Report: response of HER2-positive ductal carcinomaFrontiers in oncology · 2026Article
- [Advances in Antibody-drug Conjugates for Non-small Cell Lung Cancer after Resistance to First-line Therapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell-Derived Cardiomyocytes and FDA Adverse Events Reporting System.Clinical and translational science · 2025Article
- EGFR mutations in non-small cell lung cancer: Classification, characteristics and resistance to third-generation EGFR-tyrosine kinase inhibitors (Review).Oncology letters · 2025Review
- Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations.Journal of translational medicine · 2025Review
- Tumor-Agnostic Therapies in Practice: Challenges, Innovations, and Future Perspectives.Cancers · 2025Review
- Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches.International journal of molecular sciences · 2025Review
- Simultaneous Occurrence ofJTO clinical and research reports · 2024Article
- Cancer therapy related cardiac dysfunction as a result of Panitumumab.Cardio-oncology (London, England) · 2024Article
- Osimertinib induced adverse cardiac events: a case report.Journal of geriatric cardiology : JGC · 2023Article
- Article
- Activity of osimertinib in a patient with stage IV non-small cell lung cancer harboringTranslational lung cancer research · 2023Article
- Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs.Biomedicines · 2023Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 5 institutions in 3 countries.
Shengwu Liu *Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Shuai Li *Department of Pathology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Josephine HaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Xiaoen WangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Ting ChenLaura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
Max M QuinnDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Peng GaoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Yanxi ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Hongbin JiState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Innovation Center for Cell Signaling Network, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Darren A E CrossAstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom.
Kwok-Kin WongLaura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York. Kwok-Kin.Wong@nyumc.org.
Dana-Farber Cancer Institute · USNYU Langone Health · USAstraZeneca (United Kingdom) · GBShanghaiTech University · CNTongji University · CN
Funding
StructureP01CA154303 · NCI · DANA-FARBER CANCER INST · PI JANNE, PASI A · 2012 to 2021
$17.8MMUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung CancerR01CA166480 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2012 to 2021
$6.3MTherapeutic strategies for specific subsets of KRAS mutant lung cancersR01CA140594 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WONG, KWOK KIN · 2009 to 2017
$4.5MMUC1-C is a Target for Reversing Immune Evasion and Resistance to ImmunotherapiesU01CA233084 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2018 to 2022
$4.1MTargeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung CancerU01CA213333 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GRAY, NATHANAEL SCHIANDER, WONG, KWOK KIN · 2017 to 2021
$3.3MMechanisms of tumorigenesis in Brg1 mutant lung cancerR01CA216188 · NCI · BOSTON CHILDREN'S HOSPITAL · PI KIM, CARLA F., WONG, KWOK KIN · 2018 to 2022
$3.3MTherapeutic approaches for LKB1-deficient non-small cell lung cancerR01CA205150 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEYMACH, JOHN V., WONG, KWOK KIN · 2016 to 2020
$3.0MCredentialing Mouse Models for Immune System Therapy ResearchR01CA195740 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEROU, CHARLES M, WONG, KWOK KIN · 2015 to 2017
$1.8MNCI NIH HHS P01 CA154303NCI NIH HHS R01 CA140594NCI NIH HHS R01 CA166480NCI NIH HHS R01 CA195740NCI NIH HHS R01 CA205150NCI NIH HHS R01 CA216188NCI NIH HHS U01 CA213333NCI NIH HHS U01 CA233084
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationAcrylamidesAniline CompoundsAnimalsAntineoplastic AgentsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCell Line, TumorDisease Models, AnimalDNA Copy Number VariationsErb-b2 Receptor Tyrosine KinasesExonsHumansIndolesLung NeoplasmsMagnetic Resonance ImagingAcrylamidesAniline CompoundsAntineoplastic AgentsBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesIndolesosimertinibProtein Kinase InhibitorsPyrimidines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.